Assessing therapeutic decisions in generalized myasthenia gravis: Study protocol DOI Creative Commons
Gerardo Gutiérrez‐Gutiérrez, Rocío Gómez-Ballesteros, Javier Sotoca

et al.

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(4), P. e0322168 - e0322168

Published: April 22, 2025

Background The therapeutic landscape in generalized myasthenia gravis (gMG) has been continuously evolving recent years, with over five products approved, each different efficacy, safety, and administration profiles. With the availability of new targeted treatments, physicians are faced challenge decision-making tailored to traditional goals, individual preferences, personal experience, seeking optimal disease control a positive safety profile. In this context uncertainty multiple novel choices, study aims provide insights into preferred treatment choices neurologists managing gMG identify demographic, professional or behavioral factors influencing process. Methods This is non-interventional, cross-sectional, web-based involving 150 treating patients collaboration Spanish Society Neurology. primary endpoint will be assess preferences for attributes using conjoint analysis create hypothetical scenarios. Therapeutic inertia, described as lack initiation intensification when goals not met, evaluated secondary through 7 case scenarios simulating real clinical practice situations. Neurologists also answer survey composed professional, characteristics (user resistance behavior, care-related regret, burnout, risk attitude, empathy, work fulfilment, personality traits) recognize possible decisions. Conclusions findings contribute better understanding under changing options, which have role affecting those

Language: Английский

Assessing therapeutic decisions in generalized myasthenia gravis: Study protocol DOI Creative Commons
Gerardo Gutiérrez‐Gutiérrez, Rocío Gómez-Ballesteros, Javier Sotoca

et al.

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(4), P. e0322168 - e0322168

Published: April 22, 2025

Background The therapeutic landscape in generalized myasthenia gravis (gMG) has been continuously evolving recent years, with over five products approved, each different efficacy, safety, and administration profiles. With the availability of new targeted treatments, physicians are faced challenge decision-making tailored to traditional goals, individual preferences, personal experience, seeking optimal disease control a positive safety profile. In this context uncertainty multiple novel choices, study aims provide insights into preferred treatment choices neurologists managing gMG identify demographic, professional or behavioral factors influencing process. Methods This is non-interventional, cross-sectional, web-based involving 150 treating patients collaboration Spanish Society Neurology. primary endpoint will be assess preferences for attributes using conjoint analysis create hypothetical scenarios. Therapeutic inertia, described as lack initiation intensification when goals not met, evaluated secondary through 7 case scenarios simulating real clinical practice situations. Neurologists also answer survey composed professional, characteristics (user resistance behavior, care-related regret, burnout, risk attitude, empathy, work fulfilment, personality traits) recognize possible decisions. Conclusions findings contribute better understanding under changing options, which have role affecting those

Language: Английский

Citations

0